Form 8-K - Current report:
SEC Accession No. 0001193125-22-061339
Filing Date
2022-03-01
Accepted
2022-03-01 16:15:59
Documents
14
Period of Report
2022-03-01
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d155708d8k.htm   iXBRL 8-K 26183
2 EX-99.1 d155708dex991.htm EX-99.1 68390
6 GRAPHIC g155708g0301230545079.jpg GRAPHIC 3726
  Complete submission text file 0001193125-22-061339.txt   234647

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA ccxi-20220301.xsd EX-101.SCH 2871
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE ccxi-20220301_lab.xml EX-101.LAB 17994
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ccxi-20220301_pre.xml EX-101.PRE 11271
8 EXTRACTED XBRL INSTANCE DOCUMENT d155708d8k_htm.xml XML 3349
Mailing Address 835 INDUSTRIAL ROAD SUITE 600 SAN CARLOS CA 94070
Business Address 835 INDUSTRIAL ROAD SUITE 600 SAN CARLOS CA 94070 650-210-2900
ChemoCentryx, Inc. (Filer) CIK: 0001340652 (see all company filings)

EIN.: 943254365 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35420 | Film No.: 22698209
SIC: 2834 Pharmaceutical Preparations